KER 034
Alternative Names: KER-034Latest Information Update: 19 Jan 2024
At a glance
- Originator Keros Therapeutics
- Class Recombinant fusion proteins
- Mechanism of Action Activin inhibitors; Myostatin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Duchenne muscular dystrophy
Most Recent Events
- 03 Jan 2024 Preclinical trials in Duchenne muscular dystrophy in USA (Parenteral)
- 03 Jan 2024 Pharmacodynamics data from a preclinical trial in Duchenne muscular dystrophy by Keros Therapeutics
- 11 Jan 2019 Keros Therapeutics filled a world wide patent application for Activin receptor type iib variants and methods of use